$TGTX - On our trading list - Spec Biotech play with great risk and great potential! 100% ORR is good! Could see some interest in this one.TG Therapeutics reports triple therapy data from Phase I/II study of ublituxTG Therapeutics announced triple therapy data from the Phase I/II study of ublituximab, the company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with umbralisib, the company's oral, dual inhibitor of PI3K delta and CK1 epsilon, and venetoclax, in patients with relapsed/refractory chronic lymphocytic leukemia. Data from this trial were presented this morning during an oral session at the American Society of Hematology Annual Meeting. The overall response rate was 87% after U2 induction period at cycle 3, prior to introduction of venetoclax, in relapsed/refractory CLL patients, including patients refractory to ibrutinib. The overall response rate was 100% after cycle 7 for the triple combination. Michael Weiss, CEO of TG Therapeutics, stated, "We are extremely pleased to share the first data from the triple combination of U2 (umbralisib and ublituximab) and venetoclax, which we believe has the potential to offer patients with CLL a highly active, time-limited, and generally well tolerated treatment option. It was exciting to see that for those patients followed for at least 12 months at the time of the presentation, there was a 100% ORR, and all of those patients achieved MRD negativity in the peripheral blood, with 7 of those 9 patients also achieving MRD negativity in the bone marrow. We look forward to updating these data at future conferences as more patients are followed for 12 months and longer." Mr. Weiss continued, "We were also excited to see that 87% of patients responded to the U2 combination after just three months of treatment prior to the introduction of venetoclax. We believe this further demonstrates the activity of the U2 combination that is being studied in our UNITY-CLL Phase 3 trial, which we expect data from in the coming weeks or months." $TGTX, TG Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page